Results 41 to 50 of about 13,218 (206)

Lenacapavir initiation with concomitant primidone: A case report with therapeutic drug monitoring

British Journal of Clinical Pharmacology, EarlyView.
Lenacapavir (LEN), a first‐in‐class capsid inhibitor, has unique pharmacokinetics that enable twice‐yearly dosing. LEN is not extensively metabolized, although it is a substrate of CYP3A4, which introduces drug–drug interactions concerns. As adoption and implementation of LEN for treatment and prevention increase, additional guidance on concomitant ...
Aaron S. Devanathan, Thomas Glowa, Emily M. Thompson, Amanda J. Saylor, Thomas D. Nolin, Sharon A. Riddler, Ken S. Ho   +6 more
wiley   +1 more source

Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir [PDF]

, 2021
Objectives Cobicistat and ritonavir have different inhibitory profiles for drug transporters that could impact the distribution of co-administered drugs.
Bartels, Hanni, Decosterd, Laurent, Battegay, Manuel, Marzolini, Catia   +3 more
core  

Bridging the translational gap in clinical nanomedicine: From rational design to clinical reality

BMEMat, EarlyView.
Nanotechnology offers a multi‐faceted approach to modern healthcare, encompassing high‐sensitivity diagnostic imaging, innovative vaccine delivery, and targeted therapeutics. This review explores how these nanomedicine applications address critical challenges in cancer recurrence and the treatment of neurologic and respiratory diseases to combat rising
Ahmed H. Ghonaim, Marwa Ahmed El‐Naka, Wedad M. Nageeb, Atta Ullah Khan, Noura M. Seleem, Aliaa Abdelghafar, Doaa Zamel, Yang Liu, Qigai He, Wentao Li   +9 more
wiley   +1 more source

Evaluating Vaginal Microbiome Effects on Antiretroviral Exposure in the Female Genital Tract Using Pharmacometric and Machine Learning Approaches

Clinical Pharmacology &Therapeutics, EarlyView.
Antiretroviral pre‐exposure prophylaxis (PrEP) is less effective in women than expected, partly because drug exposure within the female genital tract is variable and may be influenced by the vaginal microbiome. We developed an integrated pharmacometrics and machine learning framework to evaluate associations between vaginal microbiome composition and ...
Diqin Yan, Lindsey B. Collins, Christopher Staley, Flavia Kiweewa Matovu, Pamala Jacobson, Melanie Nicol, Shen Cheng   +6 more
wiley   +1 more source

Pharmacokinetic Interactions of Maraviroc with Darunavir-Ritonavir, Etravirine, and Etravirine-Darunavir-Ritonavir in Healthy Volunteers: Results of Two Drug Interaction Trials

, 2011
The effects of darunavir-ritonavir at 600 and 100 mg twice daily (b.i.d.) alone, 200 mg of etravirine b.i.d. alone, or 600 and 100 mg of darunavir-ritonavir b.i.d. with 200 mg etravirine b.i.d.
Noella Ndongo, Caroline Ridgway, Rebecca Mack, Samantha Abel, Julia Hamlin, Sarah Tweedy, Thomas N. Kakuda, John Davis, Monika Schöller-Gyüre, Wendy Petit, Vanitha Sekar, Richard M. W. Hoetelmans   +11 more
core   +1 more source

Development of a physiologically‐based pharmacokinetic model for Ritonavir characterizing exposure and drug interaction potential at both acute and steady‐state conditions

CPT: Pharmacometrics &Systems Pharmacology, Volume 14, Issue 3, Page 523-539, March 2025.
Abstract Ritonavir (RTV) is a potent CYP3A inhibitor that is widely used as a pharmacokinetic (PK) enhancer to increase exposure to select protease inhibitors. However, as a strong and complex perpetrator of CYP3A interactions, RTV can also enhance the exposure of other co‐administered CYP3A substrates, potentially causing toxicity.
Lien Thi Ngo, Woojin Jung, Tham Thi Bui, Hwi‐yeol Yun, Jung‐woo Chae, Jeremiah D. Momper   +5 more
wiley   +1 more source

Factors associated with the number of drugs in darunavir/cobicistat regimens. [PDF]

, 2019
Background: Darunavir/cobicistat can be used as mono, dual, triple or more than triple therapy. Objectives: To assess factors associated with the number of drugs in darunavir/cobicistat regimens.
Knobel, Hernando, Torralba, Miguel, Negredo, Eugenia, Boix, Vicente, Martinez, Esteban, González-Doménech, Carmen María, Ocampo, Antonio, Payeras, Antoni, Alejos, Belén, Martin-Carbonero, Luz, Pérez-Elías, María Jesús, Lozano, Fernando, Montero, Marta, Gutierrez, Mar, Sanz, José, González-Cordón, Ana, Garcia-Fraile, Lucio   +16 more
core   +1 more source

Chronic alanine aminotransferase elevation in people with HIV: Time trends over 22 years and genetic predisposition

HIV Medicine, EarlyView.
Abstract Introduction Chronic elevation of alanine aminotransferase (cALT) is common in people with HIV. Published reports on cALT prevalence time trends have not been uniform. It is unknown whether genetic background is associated with cALT in people with HIV. Methods cALT was defined as ALT levels (male, >50 U/L, female, >35 U/L) at ≥2 consecutive, 6‐
Noemi R. Simon, Carlotta Mondoka, Christian W. Thorball, Isabella C. Schoepf, Lene Ryom, Irene Abela, Charles Béguelin, Urs Führer, Helen Kovari, Catia Marzolini, Annalisa Marinosci, Christian Kahlert, Luigia Elzi, David Haerry, Matthias Cavassini, Bruno Ledergerber, Jacques Fellay, Gilles Wandeler, Philip E. Tarr, the Swiss HIV Cohort Study, IA Abela, K Aebi‐Popp, A Anagnostopoulos, E Bernasconi, A Boyd, DL Braun, HC Bucher, A Calmy, M Cavassini, SE Chaudron, A Ciuffi, G Dollenmaier, M Egger, L Elzi, JS Fehr, J Fellay, S Frigerio Malossa, CA Fux, HF Günthard, A Hachfeld, DHU Haerry, B Hasse, M Hoffmann, M Huber, D Jackson‐Perry, CR Kahlert, D Kaufmann, O Keiser, RD Kouyos, H Kovari, K Kusejko, ND Labhardt, K Leuzinger, C Marzolini, KJ Metzner, N Müller, J Nemeth, D Nicca, J Notter, P Paioni, M Perreau, A Rauch, LP Salazar‐Vizcaya, P Schmid, O Segeral, RF Speck, M Stöckle, B Surial, PE Tarr, A Trkola, G Wandeler, M Weisser, S. Yerly   +72 more
wiley   +1 more source

Darunavir, Ritonavir, and Etravirine Pharmacokinetics in the Cervicovaginal Fluid and Blood Plasma of HIV-Infected Women [PDF]

, 2011
We report darunavir, ritonavir, and etravirine pharmacokinetics in cervicovaginal fluid and blood plasma for women from the G ender, R ace a nd C linical
Kristine Patterson, Patterson, Kristine, Kashuba, Angela, Joseph Mrus, Angela Kashuba, Ron Falcon, Falcon, Ron, Jennings, Steven, Mrus, Joseph, Steven Jennings   +9 more
core   +1 more source

Population Pharmacokinetics of Dolutegravir in Plasma and Cerebrospinal Fluid in Adults Living With HIV

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 10, October 2026.
ABSTRACT Characterizing dolutegravir penetration into the central nervous system is important for optimizing human immunodeficiency virus treatment outcomes, yet population‐specific pharmacokinetic data describing cerebrospinal fluid disposition and equilibration kinetics remain lacking.
Mohammed W. Ali, Sam Nightingale, Tracy Kellermann, John Joska, Alan Winston, Saye Khoo, Joseph F. Standing, Eric H. Decloedt, Ahmed A. Abulfathi   +8 more
wiley   +1 more source